Sexually Dimorphic Control of Obesity and Skeletal Muscle Lipid Metabolism by Fenofibrate

  • 투고 : 2012.11.07
  • 심사 : 2013.01.12
  • 발행 : 2013.03.31

초록

Animals show a sexual dimorphism in metabolic responses. We investigated to verify whether the peroxisome proliferator-activated receptor ${\alpha}$ ($PPAR{\alpha}$) agonist fenofibrate regulates obesity and skeletal muscle lipid metabolism with sexual dimorphism and to determine the changes in skeletal muscle expression of $PPAR{\alpha}$ target genes. After both sexes of C57BL/6J mice received a high fat diet with or without fenofibrate for 7 weeks, we examined the effects of fenofibrate on not only body weight, adipose tissue mass, and skeletal muscle lipid accumulation, but also the mRNA expression of $PPAR{\alpha}$-related genes in skeletal muscle. Male mice given a fenofibrate-supplemented high fat diet showed decreased body weight gain and adipose tissue mass compared with mice fed a high fat diet alone, whereas fenofibrate did not reduce them in high fat diet-fed female mice. Lipid accumulation in skeletal muscle was inhibited by fenofibrate in male mice, but not in female mice. Gene expression analysis revealed that fenofibrate increased the mRNA levels of $PPAR{\alpha}$ target enzymes only in male mice. Therefore, our results suggest that sex-dependence differences in obesity and intramuscular lipid levels under fenofibrate treatment could be due in part to the differences in skeletal muscle $PPAR{\alpha}$ activation between male and female mice.

키워드

과제정보

연구 과제 주관 기관 : National Research Foundation of Korea (NRF)

참고문헌

  1. Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev. 2008. 18: 426-434. https://doi.org/10.1016/j.gde.2008.07.018
  2. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000. 10: 238-245. https://doi.org/10.1016/S1050-1738(00)00077-3
  3. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008. 28: 39-46. https://doi.org/10.1161/ATVBAHA.107.160226
  4. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005. 26: 244-251. https://doi.org/10.1016/j.tips.2005.03.003
  5. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem. 1998. 273: 23786-23792. https://doi.org/10.1074/jbc.273.37.23786
  6. Chai JK, Blaha V, Meguid MM, Laviano A, Yang ZJ, Varma M. Use of orchiectomy and testosterone replacement to explore meal number-to-meal size relationship in male rats. Am J Physiol. 1999. 276: R1366-R1373.
  7. Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000. 271: 445-450. https://doi.org/10.1006/bbrc.2000.2647
  8. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, Reitman ML. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem. 2002. 277: 24484-24489. https://doi.org/10.1074/jbc.M202449200
  9. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998. 273: 29577-29585. https://doi.org/10.1074/jbc.273.45.29577
  10. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999. 20: 649-688.
  11. Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab. 2005. 90: 1791-1797. https://doi.org/10.1210/jc.2004-1936
  12. Geary N, Asarian L. Estradiol increases glucagon's satiating potency in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol. 2001. 281: R1290-R1294. https://doi.org/10.1152/ajpregu.2001.281.4.R1290
  13. Green HJ, Fraser IG, Ranney DA. Male and female differences in enzyme activities of energy metabolism in vastus lateralis muscle. J Neurol Sci. 1984. 65: 323-331. https://doi.org/10.1016/0022-510X(84)90095-9
  14. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000. 275: 16638-16642. https://doi.org/10.1074/jbc.275.22.16638
  15. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004. 53: S43-S50. https://doi.org/10.2337/diabetes.53.2007.S43
  16. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2000. 89: 465-471. https://doi.org/10.1152/jappl.2000.89.2.465
  17. Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev. 2007. 3: 33-39. https://doi.org/10.2174/157339907779802067
  18. Jeong S, Choi WC, Yoon M. Effects of fenofibrate on adipogenesis in female C57BK/6J mice. J Exp Biomed Sci. 2005. 11: 1-8.
  19. Jeong S, Choi HK, Yoon M. Morphological changes in adipose and liver tissues by 17-estradiol in female ovariectomized C57BL/6 mice. J Exp Biomed Sci. 2007. 13: 99-104.
  20. Jeong S, Kim M, Han M, Lee H, Ahn J, Kim M, Song YH, Shin C, Nam KH, Kim TW, Oh GT, Yoon M. Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. Metabolism. 2004a. 53: 607-613. https://doi.org/10.1016/j.metabol.2003.12.010
  21. Jeong S, Han M, Lee H, Kim M, Kim J, Nicol CJ, Kim BH, Choi JH, Nam KH, Oh GT, Yoon M. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004b. 53: 1284-1289. https://doi.org/10.1016/j.metabol.2004.05.003
  22. Jeong S, Yoon M. Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen. Obesity (Silver Spring). 2007. 15: 1430-1440. https://doi.org/10.1038/oby.2007.171
  23. Komi PV, Karlsson J. Skeletal muscle fibre types, enzyme activities and physical performance in young males and females. Acta Physiol Scand. 1978. 103: 210-218. https://doi.org/10.1111/j.1748-1716.1978.tb06208.x
  24. Laurent D, Gounarides JS, Gao J, Boettcher BR. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes Metab. 2009. 11: 632-636. https://doi.org/10.1111/j.1463-1326.2008.01017.x
  25. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 2001. 491: 154-158. https://doi.org/10.1016/S0014-5793(01)02146-9
  26. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004. 61: 393-416. https://doi.org/10.1007/s00018-003-3216-3
  27. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes. 2002. 51: 901-909. https://doi.org/10.2337/diabetes.51.4.901
  28. Mystkowski P, Schwartz MW. Gonadal steroids and energy homeostasis in the leptin era. Nutrition. 2000. 16: 937-946. https://doi.org/10.1016/S0899-9007(00)00458-5
  29. Serrano A, Del Arco I, Javier Pavon F, Macias M, Perez-Valero V, Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology. 2008. 54: 226-234. https://doi.org/10.1016/j.neuropharm.2007.03.007
  30. Simoneau JA, Lortie G, Boulay MR, Thibault MC, Theriault G, Bouchard C. Skeletal muscle histochemical and biochemical characteristics in sedentary male and female subjects. Can J Physiol Pharmacol. 1985. 63: 30-35. https://doi.org/10.1139/y85-005
  31. Staels B. PPAR agonists and the metabolic syndrome. Therapie. 2007. 62: 319-326. https://doi.org/10.2515/therapie:2007051
  32. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998. 98: 2088-2093. https://doi.org/10.1161/01.CIR.98.19.2088
  33. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000. 20: 1868-1876. https://doi.org/10.1128/MCB.20.5.1868-1876.2000
  34. Wade GN. Some effects of ovarian hormones on food intake and body weight in female rats. J Comp Physiol Psychol. 1975. 88: 183-193. https://doi.org/10.1037/h0076186
  35. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001. 50: 411-417. https://doi.org/10.2337/diabetes.50.2.411
  36. Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med. 2002. 34: 481-488. https://doi.org/10.1038/emm.2002.67
  37. Yoon M, Jeong S, Lee H, Han M, Kang JH, Kim EY, Kim M, Oh GT. Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Biochem Biophys Res Commun. 2003. 302: 29-34. https://doi.org/10.1016/S0006-291X(03)00088-3
  38. Yoon M. The role of PPAR${\alpha}$ in lipid metabolism and obesity: Focusing on the effects of estrogen on PPAR${\alpha}$ actions. Pharmacological Research. 2009. 60: 151-159. https://doi.org/10.1016/j.phrs.2009.02.004
  39. Yoon M. PPAR${\alpha}$ in Obesity: Sex Difference and Estrogen Involvement. PPAR Res. 2010. 2010.
  40. Zhang F, Lavan B, Gregoire FM. Peroxisome proliferator-activated receptors as attractive antiobesity targets. Drug News Perspect. 2004. 17: 661-669. https://doi.org/10.1358/dnp.2004.17.10.873918